dc.contributor.author | Grande-Pulido, E. | |
dc.contributor.author | Capdevila, J. | |
dc.contributor.author | Castellano, D. | |
dc.contributor.author | Díez, J.J. | |
dc.contributor.author | Carrato Mena, A. | |
dc.contributor.author | García-Carbonero, R. | |
dc.date.accessioned | 2024-01-24T08:46:39Z | |
dc.date.available | 2024-01-24T08:46:39Z | |
dc.date.issued | 2015 | |
dc.identifier.issn | 1569-8041 | spa |
dc.identifier.uri | https://hdl.handle.net/10641/3808 | |
dc.description.abstract | Background: The management of advanced neuroendocrine tumors (NETs) has recently changed. We assessed the activity of pazopanib after failure of other systemic treatments in advanced NETs.
Methods: This was a multicenter, open-label, phase II study evaluating pazopanib as a single agent in advanced NETs (PAZONET study). The clinical benefit rate (CBR) at 6 months was the primary end point. Translational correlation of radiological response and progression-free survival (PFS) with circulating and tissue biomarkers was also evaluated.
Results: A total of 44 patients were enrolled. Twenty-five patients (59.5%) were progression-free at 6 months (4 partial responses, 21 stable diseases) with a median PFS of 9.5 months [95% confidence interval (CI) 4.8-14.1]. The CBR varied according to prior therapy received, with 73%, 60% and 25% in patients treated with prior multitarget inhibitors, prior mTOR inhibitors and both agents, respectively. A nonsignificant increase in PFS was observed in patients presenting lower baseline circulating tumor cell (CTC) counts (9.1 versus 5.8 months; P = 0.22) and in those with decreased levels of soluble-vascular endothelial growth factor receptor-2 (sVEGFR-2) (12.6 versus 9.1 months; P = 0.067). A trend toward reduced survival was documented in patients with VEGFR3 rs307821 and rs307826 missense polymorphisms [hazard ratio (HR): 12.3; 95% CI 1.09-139.2; P = 0.042 and HR: 6.9; 95% CI 0.96-49.9; P = 0.055, respectively].
Conclusions: Pazopanib showed clinical activity in patients with advanced NETs regardless of previous treatments. Additionally, CTCs, soluble-s VEFGR-2 and VEGFR3 gene polymorphisms constitute potential biomarkers for selecting patients for pazopanib (NCT01280201).
Clinical trial number: NCT01280201. | spa |
dc.language.iso | eng | spa |
dc.publisher | Annals of Oncology. | spa |
dc.rights | Atribución-NoComercial-SinDerivadas 3.0 España | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
dc.subject | Angiogenic markers | spa |
dc.subject | Bronchial carcinoids | spa |
dc.subject | Gastroenteropancreatic tumors | spa |
dc.subject | Pazopanib | spa |
dc.subject | Polymorphisms | spa |
dc.subject | Thymic tumors | spa |
dc.title | Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE). | spa |
dc.type | journal article | spa |
dc.type.hasVersion | AM | spa |
dc.rights.accessRights | open access | spa |
dc.description.extent | 198 KB | spa |
dc.identifier.doi | 10.1093/annonc/mdv252 | spa |
dc.relation.publisherversion | https://www.annalsofoncology.org/article/S0923-7534(19)31759-4/fulltext | spa |